Younes Bathish, Neta Tuvia, Elizabeth Eshel, Tali Tal Lange, Christiane Sigrid Eberhardt, Michael Edelstein, Kamal Abu-Jabal
{"title":"透析患者对第三和第四剂 BNT162b2 疫苗的 B 细胞和 T 细胞反应。","authors":"Younes Bathish, Neta Tuvia, Elizabeth Eshel, Tali Tal Lange, Christiane Sigrid Eberhardt, Michael Edelstein, Kamal Abu-Jabal","doi":"10.1080/21645515.2023.2292376","DOIUrl":null,"url":null,"abstract":"<p><p>Patients on dialysis (PoD) are at high risk of severe morbidity and mortality from COVID-19. Characterizing long-term vaccine immune responses in these patients will help optimize vaccine schedule for PoD. This study aimed to determine whether long-term humoral and B and T cell-responses post 3<sup>rd</sup> and 4<sup>th</sup> dose of the BNT162b2 vaccine differed between PoD and controls. Non-infected PoD and controls vaccinated with BNT162b2 were recruited in Ziv Medical Center, Israel, between 2021 and 2022. Specimens were collected 1-2 months pre 3<sup>rd</sup> dose; 1-3 months post 3<sup>rd</sup> dose; 4-5 months post 3<sup>rd</sup> dose and 3-5 months post the 4<sup>th</sup> dose. Anti-SARS-CoV-2 spike (spike) specific antibodies, spike specific memory B cells, and spike specific CD154+ T cells as well as cytokines producing CD4+/CD8+ T cells were measured using standardized assays and compared between PoD and controls at each time point using Mann Whitney and Fisher's exact tests. We recruited 22 PoD and 20 controls. Antibody levels in PoD were lower compared to controls pre 3<sup>rd</sup> dose but not post 3<sup>rd</sup> and 4<sup>th</sup> doses. Frequencies of spike specific memory B cell populations were similar between PoD and controls overall. Frequencies of spike specific T cells, including those producing IFNγ and TNFα, were not lower in PoD. B and T cell mediated immune response in PoD following a 3<sup>rd</sup> and a 4<sup>th</sup> dose of the BNT162b2 vaccine was not inferior to controls up to 5 months post vaccination. Our results suggest that standard BNT162b2 vaccination is suitable for this group.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793709/pdf/","citationCount":"0","resultStr":"{\"title\":\"B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients.\",\"authors\":\"Younes Bathish, Neta Tuvia, Elizabeth Eshel, Tali Tal Lange, Christiane Sigrid Eberhardt, Michael Edelstein, Kamal Abu-Jabal\",\"doi\":\"10.1080/21645515.2023.2292376\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Patients on dialysis (PoD) are at high risk of severe morbidity and mortality from COVID-19. Characterizing long-term vaccine immune responses in these patients will help optimize vaccine schedule for PoD. This study aimed to determine whether long-term humoral and B and T cell-responses post 3<sup>rd</sup> and 4<sup>th</sup> dose of the BNT162b2 vaccine differed between PoD and controls. Non-infected PoD and controls vaccinated with BNT162b2 were recruited in Ziv Medical Center, Israel, between 2021 and 2022. Specimens were collected 1-2 months pre 3<sup>rd</sup> dose; 1-3 months post 3<sup>rd</sup> dose; 4-5 months post 3<sup>rd</sup> dose and 3-5 months post the 4<sup>th</sup> dose. Anti-SARS-CoV-2 spike (spike) specific antibodies, spike specific memory B cells, and spike specific CD154+ T cells as well as cytokines producing CD4+/CD8+ T cells were measured using standardized assays and compared between PoD and controls at each time point using Mann Whitney and Fisher's exact tests. We recruited 22 PoD and 20 controls. Antibody levels in PoD were lower compared to controls pre 3<sup>rd</sup> dose but not post 3<sup>rd</sup> and 4<sup>th</sup> doses. Frequencies of spike specific memory B cell populations were similar between PoD and controls overall. Frequencies of spike specific T cells, including those producing IFNγ and TNFα, were not lower in PoD. B and T cell mediated immune response in PoD following a 3<sup>rd</sup> and a 4<sup>th</sup> dose of the BNT162b2 vaccine was not inferior to controls up to 5 months post vaccination. Our results suggest that standard BNT162b2 vaccination is suitable for this group.</p>\",\"PeriodicalId\":49067,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793709/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2023.2292376\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2023.2292376","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
透析(PoD)患者是 COVID-19 严重发病和死亡的高危人群。鉴定这些患者的长期疫苗免疫反应将有助于优化针对透析患者的疫苗接种计划。本研究旨在确定 PoD 和对照组在接种第三剂和第四剂 BNT162b2 疫苗后的长期体液、B 细胞和 T 细胞反应是否存在差异。2021 年至 2022 年期间,以色列 Ziv 医疗中心招募了未感染的 PoD 和接种了 BNT162b2 疫苗的对照组。标本采集时间分别为第 3 次接种前 1-2 个月、第 3 次接种后 1-3 个月、第 3 次接种后 4-5 个月和第 4 次接种后 3-5 个月。使用标准化检测方法测量抗 SARS-CoV-2 穗状病毒(穗状病毒)特异性抗体、穗状病毒特异性记忆 B 细胞、穗状病毒特异性 CD154+ T 细胞以及产生 CD4+/CD8+ T 细胞的细胞因子,并使用曼惠特尼和费雪精确检验比较 PoD 和对照组在每个时间点的情况。我们招募了 22 名 PoD 和 20 名对照组。与对照组相比,PoD 在第 3 次用药前的抗体水平较低,但在第 3 次和第 4 次用药后的抗体水平并不低。尖峰特异性记忆 B 细胞群的频率在总体上与 PoD 和对照组相似。尖峰特异性 T 细胞(包括产生 IFNγ 和 TNFα 的细胞)的数量在 PoD 中并不低。接种第三剂和第四剂 BNT162b2 疫苗后,PoD 的 B 细胞和 T 细胞介导的免疫反应在接种后 5 个月内不低于对照组。我们的结果表明,标准的 BNT162b2 疫苗接种适用于该群体。
B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients.
Patients on dialysis (PoD) are at high risk of severe morbidity and mortality from COVID-19. Characterizing long-term vaccine immune responses in these patients will help optimize vaccine schedule for PoD. This study aimed to determine whether long-term humoral and B and T cell-responses post 3rd and 4th dose of the BNT162b2 vaccine differed between PoD and controls. Non-infected PoD and controls vaccinated with BNT162b2 were recruited in Ziv Medical Center, Israel, between 2021 and 2022. Specimens were collected 1-2 months pre 3rd dose; 1-3 months post 3rd dose; 4-5 months post 3rd dose and 3-5 months post the 4th dose. Anti-SARS-CoV-2 spike (spike) specific antibodies, spike specific memory B cells, and spike specific CD154+ T cells as well as cytokines producing CD4+/CD8+ T cells were measured using standardized assays and compared between PoD and controls at each time point using Mann Whitney and Fisher's exact tests. We recruited 22 PoD and 20 controls. Antibody levels in PoD were lower compared to controls pre 3rd dose but not post 3rd and 4th doses. Frequencies of spike specific memory B cell populations were similar between PoD and controls overall. Frequencies of spike specific T cells, including those producing IFNγ and TNFα, were not lower in PoD. B and T cell mediated immune response in PoD following a 3rd and a 4th dose of the BNT162b2 vaccine was not inferior to controls up to 5 months post vaccination. Our results suggest that standard BNT162b2 vaccination is suitable for this group.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.